While receiving therapy, patients should be monitored for anaphylaxis and infusion reactions.

Subjects with pre-existing congestive heart failure and receiving pegloticase should be monitored periodically for CHF exacerbations. Immunogenicity to therapy may occur while being treated with pegloticase.